M
Marleen Kok
Researcher at Netherlands Cancer Institute
Publications - 83
Citations - 3836
Marleen Kok is an academic researcher from Netherlands Cancer Institute. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 26, co-authored 65 publications receiving 1982 citations.
Papers
More filters
Journal ArticleDOI
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.
Myriam Chalabi,Lorenzo F. Fanchi,Krijn K. Dijkstra,José G van den Berg,Arend G. J. Aalbers,Karolina Sikorska,Marta Lopez-Yurda,Cecile Grootscholten,Geerard L. Beets,Geerard L. Beets,Petur Snaebjornsson,Monique Maas,Marjolijn Mertz,Vivien Veninga,Gergana Bounova,Annegien Broeks,Regina G. H. Beets-Tan,Regina G. H. Beets-Tan,Thomas R de Wijkerslooth,Anja U. van Lent,Hendrik A Marsman,Elvira Nuijten,Niels F. M. Kok,Maria Kuiper,Wieke H M Verbeek,Marleen Kok,Monique E. van Leerdam,Ton N. Schumacher,Emile E. Voest,John B. A. G. Haanen +29 more
TL;DR: The data indicate that neoadjuvant immunotherapy may have the potential to become the standard of care for a defined group of colon cancer patients when validated in larger studies with at least 3 years of disease-free survival data.
Journal ArticleDOI
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.
Leonie Voorwerk,Maarten Slagter,Hugo M. Horlings,Karolina Sikorska,Koen Van de Vijver,Koen Van de Vijver,Michiel de Maaker,Iris Nederlof,Roelof J.C. Kluin,Sarah Warren,SuFey Ong,T. Wiersma,Nicola S. Russell,Ferry Lalezari,Philip C. Schouten,Noor A. M. Bakker,Steven L. C. Ketelaars,Dennis Peters,Charlotte A.H. Lange,Erik van Werkhoven,Harm van Tinteren,I.A.M. Mandjes,Inge Kemper,Suzanne Onderwater,Myriam Chalabi,Sofie Wilgenhof,John B. A. G. Haanen,Roberto Salgado,Karin E. de Visser,Gabe S. Sonke,Lodewyk F. A. Wessels,Sabine C. Linn,Ton N. Schumacher,Christian U. Blank,Marleen Kok +34 more
TL;DR: A pick-the-winner clinical trial design in patients with metastatic triple-negative breast cancer shows that immune induction with doxorubicin or cisplatin may improve clinical responses to PD-1 blockade and induce a more favorable tumor microenvironment.
Journal ArticleDOI
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.
Daniel J. McGrail,Patrick G. Pilie,Naim U. Rashid,Leonie Voorwerk,Maarten Slagter,Marleen Kok,Eric Jonasch,Mustafa Khasraw,Amy B. Heimberger,Bora Lim,NT Ueno,Jennifer K. Litton,Renata Ferrarotto,Jeffrey T. Chang,S. L. Moulder,Sy Lin +15 more
TL;DR: In this article, the authors compared approaches to determine TMB and identify the correlation between predicted neoantigen load and CD8 T cells, and found that TMB-H tumors exhibited a 39.8% ORR to ICB [95% confidence interval (CI) 34.9-44.8], which was significantly higher than that observed in low TMB (TMB-L) tumors.
Journal ArticleDOI
Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials
Myriam Chalabi,A. Cardona,D.R. Nagarkar,A.M. Dhawahir Scala,David R. Gandara,Achim Rittmeyer,Matthew L. Albert,Thomas Powles,Marleen Kok,F.G. Herrera +9 more
TL;DR: Data suggest that ATB or PPI use in patients with metastatic NSCLC is associated with poor outcome and may influence the efficacy of ICI.
Journal ArticleDOI
The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice
Paula I. Gonzalez-Ericsson,Elisabeth Specht Stovgaard,Luz F. Sua,Emily Reisenbichler,Zuzana Kos,Jodi M. Carter,Stefan Michiels,John Le Quesne,John Le Quesne,Torsten O. Nielsen,Anne-Vibeke Lænkholm,Stephen B. Fox,Stephen B. Fox,Julien Adam,John M. S. Bartlett,John M. S. Bartlett,David L. Rimm,Cecily Quinn,Dieter Peeters,Maria Vittoria Dieci,Anne Vincent-Salomon,Ian A. Cree,Akira I Hida,Justin M. Balko,Harry R Haynes,Harry R Haynes,Isabel Frahm,Gabriela Acosta‐Haab,Marcelo Luiz Balancin,Enrique Bellolio,Wentao Yang,Pawan Kirtani,Tomoharu Sugie,Anna Ehinger,Carlos A. Castaneda,Marleen Kok,Heather L. McArthur,Kalliopi P. Siziopikou,Sunil Badve,Susan Fineberg,Allen M. Gown,Giuseppe Viale,Stuart J. Schnitt,Stuart J. Schnitt,Giancarlo Pruneri,Frédérique Penault-Llorca,Stephen M. Hewitt,E. Aubrey Thompson,Kimberly H. Allison,William Fraser Symmans,Andrew M. Bellizzi,Edi Brogi,David A Moore,Denis Larsimont,Deborah A. Dillon,Alexander J. Lazar,Huang-Chun Lien,Matthew P. Goetz,Glenn Broeckx,Khalid El Bairi,Nadia Harbeck,Ashley Cimino-Mathews,Christos Sotiriou,Sylvia Adams,Shi‐wei Liu,Sibylle Loibl,I-Chun Chen,Sunil R. Lakhani,Jonathan Juco,Carsten Denkert,Elizabeth F Blackley,Sandra Demaria,Roberto A. Leon-Ferre,Oleg Gluz,Dimitrios Zardavas,Kenneth Emancipator,Scott Ely,Sherene Loi,Sherene Loi,Roberto Salgado,Melinda E. Sanders +80 more
TL;DR: A risk‐management framework is proposed that may help mitigate the risks of suboptimal patient selection for immuno‐therapeutic approaches in clinical trials and daily practice based on combined TILs/PD‐L1 assessment in BC.